Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
REGULATORY
Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
The Ministry of Health, Labor and Welfare (MHLW) will add a slew of generics to the NHI price list on June 14, including the so-called “biosame” version of the Nesp (darbepoetin alfa) renal anemia drug, according to the official gazette…
To read the full story
Related Article
- Daiichi Sankyo Espha Rolls Out AstraZeneca’s 3 Cancer AGs; Gx Onslaught for Lonasen, Urief
June 14, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
February 15, 2019
REGULATORY
- Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
- Govt Earmarks 3 Billion Yen for AMED's Organ-on-Chip Project
June 21, 2019
- ICH to Discuss Use of RWD in Post-Marketing Safety Measures: Amsterdam Meeting
June 20, 2019
- MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
- MHLW Orders Label Revisions for Metformin, Blanket Contraindication for Patients with Severe Kidney Impairment
June 19, 2019
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…